ONCOLOGY AND MOLECULAR PATHOLOGY

STUDENTS ARE KINDLY REQUESTED TO ENROLL ON THE MOODLE PLATFORM

BIOMEDICAL/BIOMOLECULAR
Molecular Pathology (3CFU)
Oncology (3 CFU)

NEUROBIOLOGICAL
Molecular Pathology (3 CFU)
Oncology (2 CFU)
Neuropathology (1 CFU – prof. L. Durelli, lesson time-table to be defined)

Didactic material will be published on Moodle

Exam modality: written test on Moodle

Information on course syllabus, time tables, exam enrollment, suggested textbooks:

http://cmb.campusnet.unito.it/do/home.pl

http://cmb.campusnet.unito.it/do/corsi.pl/Show?_id=g12a

DISEASE

- Dynamic condition
- Morpho-functional alteration of one or more organ/tissue
- Acute or chronic
- Localized or systemic

Etiology = studies the causes of disease

Pathogenesis = starting from etiology, studies the mechanisms leading to disease

ETIOLOGY

Monofactorial and multifactorial diseases

CAUSES OF DISEASE

Intrinsic (es. on genetic basis)

Extrinsic (chemical, physical, microbiological, diet-related, etc.)

Both extrinsic and intrinsic causes can contribute to a disease

Idiopathic disease: unknown etiology

DAMAGE RESPONSE IN CELLS AND TISSUES



CELL ADAPTATIONS

ATTAINMENT OF A NEW STEADY STATE

PROGRESSIVE

HYPERTROPHY — CELL NUMBER (HYPERPLASIA)
CELL VOLUME

REGRESSIVE

HYPOPLASIA

HYPOTROPHY/ATROPHY

HYPERPLASIA

INCREASED CELL NUMBER IN ORGANS/TISSUES

GENERALLY IN LABILE TISSUES

BALANCE WITH STIMULUS ENTITY

REVERSIBLE

due to physiologic/pathologic hormonal stimuli
compensatory
due to increased functional requirement (polyglobulia)

PATHOGENETIC MECHANISMS

- increased growth factor levels
- increased expression growth factor receptors
- signal transduction pathways activation
- RESULT: cell proliferation induction
  stem cell recruitment and differentiation

Increased risk of tumor development

http://www-3.unipv.it/webbio/anatcomp/bertone/TavoleAnatomiaMicroscopica/27%20prostata.JPG



Normal prostate

Here is one of the nodules of hyperplastic prostate, with many glands along with some intervening stroma. The cells making up the glands are normal in appearance, but there are just too many of them



Hyperplastic prostate

http://library.med.utah.edu/WebPath

LIVER RIGENERATION





Columbano e Shinozuka, 1996


RL
LL
M
Regeneration
RL
C
PARTIAL HEPATECTOMY
cyclins
mdm2
p53
c-myc
c-fos,
c-jun
bclx
DNA replication
Mitosis
10X
6X
4X
2X
Normal
Transcript levels
0 4 8 12 16 20 24 28 32 36 40 44
Hours
4
3
2
1
DNA replication and mitosis
© Elsevier 2005


Growth factors
Progression
S
Priming
Cytokines
G0
G1
G2
Quiescence
M
PARTIAL HEPATECTOMY
Cytokines
TNF
IL-6
Others
Priming
Growth factors
HGF
TGF-α
Others
Proliferation
Adjuvants
Norepinephrine
Insulin
Thyroid hormone
Growth hormone
Growth inhibitors
TGF-β
Activin
Others
Growth inhibition
Cell cycle inhibitors
Growth factors
Metabolic demands
© Elsevier 2005

POLYGLOBULIA: INCREASED NYUMBER OF CIRCULATING ERYTHROCYTES
absolute or secondart to chronic hypoxia





HYPERTROPHY

INCREASED CELL VOLUME

PHYSIOLOGIC OR PATHOLOGIC, REVERSIBLE
- in low (liver, muscle) and very low turnover tissues (nervous)

INCREASED FUNCTION
- exercise (skeletal muscle)
- chronic blood overload

SPECIFIC HORMONAL STIMULI
- pregnancy, breast-feeding
- benign prostatic hyperplasia

PATHOGENETIC MECHANISMS
- mechanical stimuli (muscle contraction)
- trophic stimuli (growth factors, vasoactive factors)
  - enhanced protein synthesis (riduced degradation)
  - protein type change (muscle)
  - embryonal gene re-expression (atrial natriuretic factor)

Hypertrophic uterus (pregnancy)



FIGURE 1–3B Physiologic hypertrophy of the uterus during pregnancy. **A,** Gross appearance of a normal uterus *(right)* and a gravid uterus (removed for postpartum bleeding) *(left)*. **B,** Small spindle-shaped uterine smooth muscle cells from a normal uterus, compared with **C,** large plump cells from the gravid uterus, at the same magnification.





Ipertrofia muscolare



AUMENTATO ESERCIZIO



GFP

↑GROWTH FACTOR
↑EXPRESSION



IGF-1



DA MUTAZIONE DEL GENE PER LA MIOSTATINA

MYOSTATIN

TGF-β family member, negatively regulates muscle mass





Myostatin signaling pathway



Argilés et al., 2012

CARDIAC HYPERTROPHY

HYPERTENSION

VALVULOPATHY

INFARCT

↑ CARDIAC WORK

↑ WALL STRESS

CELL ELONGATION

HYPERTROPHY/EXPANSION

CARDIAC DYSFUNCTION

cardiac failure
arhyithmia
neurohumoral stimulation

↑ heart size
↑ protein synthesis
- **early gene ad fetal gene program activation**
- **appearance of altered proteins**
- **fibrosis**
- **insufficient vascularization**


HYPERTRPHIC STIMULI
Ras
Calmodulin
PI3K/Akt
NO
MAPK
CAM-K
Calcineurin
GSK3-β
CGMP
TRANSCRIPTION FACTORS
↑GENE EXPRESSION
TGFβ, IGF-1, FGF, angiotensin-II, α-adrenergic agonists,
βMHC, MLC, cardiac α-actin, embryonalgenes
HYPERTROPHY

COMPENSATORY HYPERTROPHY

DUE TO LACK OR LOSS OF FUNCTION OF ONE MEMBER OF PAIRED ORGANS (es.: kidney, adrenal)

KIDNEY

Enlarged existing glomeruli, capillary elongation

Hyperplasia occurs, without new glomeruli/tubules

Slow response: compensation by the remaining kidney through circulation changes

OTHER EXAMPLES

CAUSE	EXAMPLE
•endocrine stimulation	estrogens → hypertrophy/hyperplasia in uterus
•humoral mediators	cytokines → leucocyte hypertrophy/hyperplasia
•mechanic factors	skin traction → hypertrophy/hyperplasia in skin
•Drugs	β-adrenergic agonists → muscle hypertrophy

HYPOTROPHY/ATROPHY

REDUCED CELL DIMENSION/FUNCTIONS

PHYSIOLOGIC (embryonal development, restoration normal organ/tissue dimensions)

PATHOLOGIC CAUSES:reduced work load
compression
denervation
reduced blood supply
malnutrition
reduced endorcine stimulation
aging
immunologic causes (es. pernicious anemia)
drugs

Muscle atrophy





Some of these skeletal muscle fibers here show atrophy, compared to normal fibers. The number of cells is the same as before the atrophy occurred, but the size of some fibers is reduced. This is a response to injury by "downsizing" to conserve the cell. In this case, innervation to the small, atrophic fibers was lost (trichrome stain).

Muscle atrophy in cancer cachexia







Brain atrophy







http://missinglink.ucsf.edu/lm/ids_104_neurodegenerative/Case1/Case1Gross.htm

CELL DAMAGE

Severe damages alter fundamental cell structure/function → cell death: NECROSIS (death by colloido-osmotic lyis) and APOPTOSIS (death by condensation)



MORPHOLOGICAL ASPECTS OF CELL DEATH



Electron microscopy images of cells undergoing different death processes.

a | Pyknosis, chromatin condensation and plasma membrane blebbing, are morphological traits of **apoptosis.**

b | Nuclear membrane dilatation, circumscribed chromatin condensation and increased cell volume (oncosis), are morphological manifestations of **necrosis.**

c | **Autophagic vacuolization**.

Nature Rev mol cell biol, Kroemer 2011, 12, 385

NECROSIS



APOPTOSIS



Kidney infarct and necrosis



This is an example of coagulative necrosis. This is the typical pattern with ischemia and infarction (loss of blood supply and resultant tissue anoxia). Here, there is a wedge-shaped pale area of coagulative necrosis (infarction) in the renal cortex of the kidney.

Necrosis

Normal myocardium
In contrast with skeletal muscle, cardiac myofibers interdigitate. A myocyte can comprise a portion of more than one myofiber, as seen in the upper central portion of this photo.





Myocardium: cells are dying as a result of ischemic injury from coronary artery occlusion. This is early in the process of necrosis. The nuclei of the myocardial fibers are being lost. The cytoplasm is losing its structure, because no well-defined cross-striations are seen.

http://library.med.utah.edu/WebPath

APOPTOSIS

MORPHOLOGY

LOSS OF MICROVILLI AND INTERCELLULAR JUNCTIONS

'BLEBBING'

REDUCED CELL VOLUME

MEMBRANE AND INTRACELLULAR ORGANELLE PRESERVATION

NUCLEAR MORPHO-FUNCTIONAL ALTERATIONS

CELL FRAGMENTATION IN APOPTOTIC BODIES

BIOCHEMISTRY

PHOSPHATIDYLSERINE EXTERNALIZATION

CASPASE, TRANSGLUTAMINASE, ENDONUCLEASE ACTIVATION



http://www-3.unipv.it/webbio/anatcomp/bertone/TavoleAnatomiaMicroscopica/27%20prostata.JPG

Fegato normale



Normal liver



Normal liver

Liver: apoptosis





Liver: Fas-induced apoptosis









FIGURE 1–24 Mechanisms of apoptosis. The two pathways of apoptosis differ in their induction and regulation, and both culminate in the activation of "executioner" caspases. The induction of apoptosis by the mitochondrial pathway involves the action of sensors and effectors of the Bcl-2 family, which induce leakage of mitochondrial proteins. Also shown are some of the anti-apoptotic proteins ("regulators") that inhibit mitochondrial leakiness and cytochrome *c*–dependent caspase activation in the mitochondrial pathway. In the death receptor pathway engagement of death receptors leads directly to caspase activation. The regulators of death receptor–mediated caspase activation are not shown. ER, endoplasmic reticulum; TNF, tumor necrosis factor.



Ischemia-derived cell damage: reversible and irreversible

N.B.: ischemia *vs* hypoxia
ISCHEMIA reduced blood supply
IPOSSIA reduced O_2 supply

Reactive oxygen species (ROS) and cell damage



DEGENERATIVE PROCESSES

MECHANISMS OF INTRACELLULAR ACCUMULATION

Metabolic alteration:
Liver steatosis (tryglicerides)

A



B



Altered protein folding and transport
(es. antitrypsine deficit)

Hereditary deficit of lysosomal enzymes
→ no substrate degradation

C



D



Accumulation of non-degradable material
(es. Fe = hemosiderosis)

Liver, CCl_4 damage:

A. steatosis B. necrosis



Liver steatosis



normal



steatosis

chirrosis



HCC




Free fatty acids
UPTAKE
Acetate
Fatty acids
Oxidation to ketone bodies, CO_2
α-Glycero-phosphate
Phospholipids
Cholesterol esters
CATABOLISM
Triglycerides
Apoprotein
Lipoproteins
SECRETION
Lipid accumulation
A

Liver: Mallory bodies



Mallory bodies (the red globular material) composed of cytoskeletal filaments in liver cells chronically damaged from alcoholism. These are a type of "intermediate" filament between the size of actin (thin) and myosin (thick). Not specific of alcoholic hepatitis, also found in non-alcoholic fatty liver disease (NAFLD), primary biliary chirrosis (PBC), Wilson disease, hepatocellular carcinoma.

Liver: hemosiderin accumulation



FIGURE 1–34B Hemosiderin granules in liver cells. **A,** H+E stain showing golden-brown, finely granular pigment. **B,** Prussian blue stain, specific for iron (seen as blue granules).


TISSUE NECROSIS OUTCOMES
acute inflammation
labile/stabile cells
perennial cells
persistent damaging agent
regeneration
healing
chronic inflammation
restoration of normal strutcure/function
persistent damaging agent
no more damaging agent
scare formation loss of function